A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504897-39-00

Acronym

DO2.22.01

Enrollment

Registered

2023-05-31

Start date

2023-04-13

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or refractory solid tumours (Part 1), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) (Part 2)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France, Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026